Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.62 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.44 |
| ▸ | FABP4 | P15090 | 5/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 4/20 | 0.39 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | ATF4 | P18848 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928964 | 0.95 | CXCR2 (0.62) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL3933368 | 0.92 | CXCR2 (0.73) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL4514705 | 0.89 | CXCR2 (0.52) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL3928226 | 0.86 | CXCR2 (0.82) | CXCR2ERAP1FABP4CXCR5 | |
| SCHEMBL3924926 | 0.86 | CXCR2 (0.54) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL3926345 | 0.85 | CXCR2 (0.51) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL485432 | 0.84 | CXCR2 (0.54) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL4526031 | 0.83 | CXCR2 (0.49) | CXCR2ERAP1DRD2DRD3 | |
| SCHEMBL3929933 | 0.83 | CXCR2 (0.60) | CXCR2ERAP1FABP4FABP5CXCR5 | |
| SCHEMBL3926776 | 0.83 | CXCR2 (0.49) | CXCR2ERAP1FABP4FABP5CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227625-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885ERAP1 2099/4885FABP4 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.